pharmiweb.com today archive

17 Dec 14

The Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) have welcomed the Cell Therapy Catapults announcement that it will build its new 55million state-of-the-art cell therapy manufacturing centre in Stevenage.

It was announced that the Cell Therapy Catapult had been awarded 55m to design, build and establish a manufacturing centre in the Chancellors budget in March this year. The establishment of a cell therapy manufacturing centre was a key recommendation made by the Medicines Manufacturing Industry Partnership (MMIP) to the Ministerial Industry Strategy group which is chaired by the Secretary of State for Health Jeremy Hunt MP at the end of last year. The MMIP was jointly established by the ABPI and the BIA to create an attractive and innovation-rich environment in medicines manufacturing.

Welcoming the decision to establish the centre in Stevenage, ABPI project Director for manufacturing James Christie said:

The ABPI warmly welcomes this announcement. The decision to establish this centre is another step forward in the medicines manufacturing supply chain of advanced therapies' demonstrating the UK leading position in this area and it will help to ensure UK competitiveness in medicines manufacturing.

Commenting on the announcement Steve Bates CEO of the BioIndustry Association said:

The UK cell therapy industry has huge potential, and investments such as this will allow the sector to progress from a strong R&D base to the manufacture of commercial stage products, enabling the UK to become a landing pad in Europe for cell therapy.Todays announcement represents another milestone in the establishment of the UK as a global leader in medicines manufacturing.

Read this article:
pharmiweb.com today archive